Maintaining Intestinal Health: The Genetics and Immunology of Very Early Onset Inflammatory Bowel Disease

Cellular and Molecular Gastroenterology and Hepatology

Volumn 1, Issue 5, 2015, Pages 462-476

  Kelsen, Judith R ^a   Baldassano, Robert N ^a   Artis, David ^b   Sonnenberg, Gregory F ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Inflammatory Bowel Disease; Mucosal Immunology; Very Early Onset Inflammatory Bowel Disease; Whole Exome Sequencing

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; B LYMPHOCYTE RECEPTOR; CD40 ANTIGEN; CD40 LIGAND; CD45 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 23; INTERLEUKIN 33; JANUS KINASE 3; PROTEIN KINASE ZAP 70; STAT1 PROTEIN; STAT3 PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ADAPTIVE IMMUNITY; CHRONIC GRANULOMATOUS DISEASE; DISEASE SEVERITY; GENE INTERACTION; GENETIC VARIABILITY; GENETICS; HUMAN; HYPER IGE SYNDROME; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; NONHUMAN; OMENN SYNDROME; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; WISKOTT ALDRICH SYNDROME;

EID: 84939222276     PISSN: None     EISSN: 2352345X     Source Type: Journal    
DOI: 10.1016/j.jcmgh.2015.06.010     Document Type: Review

References (153)

1. Maloy K.J., Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011, 474:298-306.
2. Maynard C.L., Elson C.O., Hatton R.D., et al. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012, 489:231-241.
3. Hooper L.V., Macpherson A.J. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol 2010, 10:159-169.
4. Hooper L.V., Littman D.R., Macpherson A.J. Interactions between the microbiota and the immune system. Science 2012, 336:1268-1273.
5. Belkaid Y., Hand T.W. Role of the microbiota in immunity and inflammation. Cell 2014, 157:121-141.
6. Khor B., Gardet A., Xavier R.J. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011, 474:307-317.
7. Abraham C., Cho J.H. Inflammatory bowel disease. NEngl J Med 2009, 361:2066-2078.
8. Lodes M.J., Cong Y., Elson C.O., et al. Bacterial flagellin is a dominant antigen in Crohn disease. JClin Invest 2004, 113:1296-1306.
9. Baumgart M., Dogan B., Rishniw M., et al. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of clostridiales in Crohn's disease involving the ileum. ISME J 2007, 1:403-418.
10. Darfeuille-Michaud A., Boudeau J., Bulois P., et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004, 127:412-421.
11. Dalwadi H., Wei B., Kronenberg M., et al. The Crohn's disease-associated bacterial protein I2 is a novel enteric T cell superantigen. Immunity 2001, 15:149-158.
12. Walker A.W., Sanderson J.D., Churcher C., et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol 2011, 11:7.
13. Willing B., Halfvarson J., Dicksved J., et al. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm Bowel Dis 2009, 15:653-660.
14. Willing B.P., Dicksved J., Halfvarson J., et al. Apyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 2010, 139:1844-1854.e1.
15. Martin H.M., Campbell B.J., Hart C.A., et al. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology 2004, 127:80-93.
16. Benchimol E.I., Guttmann A., Griffiths A.M., et al. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. Gut 2009, 58:1490-1497.
17. Uhlig H.H. Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease. Gut 2013, 62:1795-1805.
18. de Ridder L., Weersma R.K., Dijkstra G., et al. Genetic susceptibility has a more important role in pediatric-onset Crohn's disease than in adult-onset Crohn's disease. Inflamm Bowel Dis 2007, 13:1083-1092.
19. Benchimol E.I., Mack D.R., Nguyen G.C., et al. Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease. Gastroenterology 2014, 147:803-813.e7.
20. Glocker E., Grimbacher B. Inflammatory bowel disease: is it a primary immunodeficiency?. Cell Mol Life Sci 2012, 69:41-48.
21. Ruemmele F.M., El Khoury M.G., Talbotec C., et al. Characteristics of inflammatory bowel disease with onset during the first year of life. JPediatr Gastroenterol Nutr 2006, 43:603-609.
22. Cannioto Z., Berti I., Martelossi S., et al. IBD and IBD mimicking enterocolitis in children younger than 2 years of age. Eur J Pediatr 2009, 168:149-155.
23. Glocker E.O., Kotlarz D., Boztug K., et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. NEngl J Med 2009, 361:2033-2045.
24. Biank V., Broeckel U., Kugathasan S. Pediatric inflammatory bowel disease: clinical and molecular genetics. Inflamm Bowel Dis 2007, 13:1430-1438.
25. Glocker E.O., Frede N., Perro M., et al. Infant colitis-it's in the genes. Lancet 2010, 376:1272.
26. Agarwal S., Mayer L. Diagnosis and treatment of gastrointestinal disorders in patients with primary immunodeficiency. Clin Gastroenterol Hepatol 2013, 11:1050-1063.
27. Mao H., Yang W., Lee P.P., et al. Exome sequencing identifies novel compound heterozygous mutations of IL-10 receptor 1 in neonatal-onset Crohn's disease. Genes Immun 2012, 13:437-442.
28. Worthey E.A., Mayer A.N., Syverson G.D., et al. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet Med 2011, 13:255-262.
29. Avitzur Y., Guo C., Mastropaolo L.A., et al. Mutations in tetratricopeptide repeat domain 7A result in a severe form of very early onset inflammatory bowel disease. Gastroenterology 2014, 146:1028-1039.
30. Kammermeier J., Drury S., James C.T., et al. Targeted gene panel sequencing in children with very early onset inflammatory bowel disease-evaluation and prospective analysis. JMed Genet 2014, 51:748-755.
31. Jostins L., Ripke S., Weersma R.K., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491:119-124.
32. Durandy A., Kracker S., Fischer A. Primary antibody deficiencies. Nat Rev Immunol 2013, 13:519-533.
33. Muise A.M., Snapper S.B., Kugathasan S. The age of gene discovery in very early onset inflammatory bowel disease. Gastroenterology 2012, 143:285-288.
34. Uhlig H.H., Schwerd T., Koletzko S., et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology 2014, 147:990-1007.e3.
35. Heyman M.B., Kirschner B.S., Gold B.D., et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. JPediatr 2005, 146:35-40.
36. Mamula P., Telega G.W., Markowitz J.E., et al. Inflammatory bowel disease in children 5 years of age and younger. Am J Gastroenterol 2002, 97:2005-2010.
37. Aloi M., Lionetti P., Barabino A., et al. Phenotype and disease course of early-onset pediatric inflammatory bowel disease. Inflamm Bowel Dis 2014, 20:597-605.
38. Hsieh K.H., Chang M.H., Lee C.Y., Wang C.Y. Wiskott-Aldrich syndrome and inflammatory bowel disease. Ann Allergy 1988, 60:429-431.
39. Marks D.J., Seymour C.R., Sewell G.W., et al. Inflammatory bowel diseases in patients with adaptive and complement immunodeficiency disorders. Inflamm Bowel Dis 2010, 16:1984-1992.
40. Alangari A., Alsultan A., Adly N., et al. LPS-responsive beige-like anchor (LRBA) gene mutation in a family with inflammatory bowel disease and combined immunodeficiency. JAllergy Clin Immunol 2012, 130:481-488.e2.
41. Seidel M.G. Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment. Blood 2014, 124:2337-2344.
42. Zhang Q., Davis J.C., Lamborn I.T., et al. Combined immunodeficiency associated with DOCK8 mutations. NEngl J Med 2009, 361:2046-2055.
43. Randall K.L., Lambe T., Johnson A.L., et al. Dock8 mutations cripple B cell immunological synapses, germinal centers and long-lived antibody production. Nat Immunol 2009, 10:1283-1291.
44. Brooks E.G., Filipovich A.H., Padgett J.W., et al. T-cell receptor analysis in Omenn's syndrome: evidence for defects in gene rearrangement and assembly. Blood 1999, 93:242-250.
45. Kato M., Kimura H., Seki M., et al. Omenn syndrome-review of several phenotypes of Omenn syndrome and RAG1/RAG2 mutations in Japan. Allergol Int 2006, 55:115-119.
46. Schuetz C., Huck K., Gudowius S., et al. An immunodeficiency disease with RAG mutations and granulomas. NEngl J Med 2008, 358:2030-2038.
47. Washington K., Stenzel T.T., Buckley R.H., et al. Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglobulinemia. Am J Surg Pathol 1996, 20:1240-1252.
48. Malamut G., Verkarre V., Suarez F., et al. The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease. Am J Gastroenterol 2010, 105:2262-2275.
49. Cunningham-Rundles C., Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999, 92:34-48.
50. van Zelm M.C., Reisli I., van der Burg M., et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. NEngl J Med 2006, 354:1901-1912.
51. Zonana J., Elder M.E., Schneider L.C., et al. Anovel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am J Hum Genet 2000, 67:1555-1562.
52. Marks D.J., Miyagi K., Rahman F.Z., et al. Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn's disease. Am J Gastroenterol 2009, 104:117-124.
53. Patey-Mariaud de Serre N., Canioni D., Ganousse S., et al. Digestive histopathological presentation of IPEX syndrome. Mod Pathol 2009, 22:95-102.
54. Levy M., Arion A., Berrebi D., et al. Severe early-onset colitis revealing mevalonate kinase deficiency. Pediatrics 2013, 132:e779-e783.
55. Demir A., Akyuz F., Gokturk S., et al. Small bowel mucosal damage in familial Mediterranean fever: results of capsule endoscopy screening. Scand J Gastroenterol 2014, 49:1414-1418.
56. Gurkan O.E., Yilmaz G., Aksu A.U., et al. Colonic lymphoid nodular hyperplasia in childhood: causes of familial Mediterranean fever need extra attention. JPediatr Gastroenterol Nutr 2013, 57:817-821.
57. Chalaris A., Gewiese J., Paliga K., et al. ADAM17-mediated shedding of the IL6R induces cleavage of the membrane stub by gamma-secretase. Biochim Biophys Acta 2010, 1803:234-245.
58. Blaydon D.C., Biancheri P., Di W.L., et al. Inflammatory skin and bowel disease linked to ADAM17 deletion. NEngl J Med 2011, 365:1502-1508.
59. Karamchandani-Patel G., Hanson E.P., Saltzman R., et al. Congenital alterations of NEMO glutamic acid 223 result in hypohidrotic ectodermal dysplasia and immunodeficiency with normal serum IgG levels. Ann Allergy Asthma Immunol 2011, 107:50-56.
60. Zimmer K.P., Schumann H., Mecklenbeck S., Bruckner-Tuderman L. Esophageal stenosis in childhood: dystrophic epidermolysis bullosa without skin blistering due to collagen VII mutations. Gastroenterology 2002, 122:220-225.
61. Sadler E., Klausegger A., Muss W., et al. Novel KIND1 gene mutation in Kindler syndrome with severe gastrointestinal tract involvement. Arch Dermatol 2006, 142:1619-1624.
62. Ussar S., Moser M., Widmaier M., et al. Loss of Kindlin-1 causes skin atrophy and lethal neonatal intestinal epithelial dysfunction. PLoS Genet 2008, 4:e1000289.
63. Kern J.S., Herz C., Haan E., et al. Chronic colitis due to an epithelial barrier defect: the role of kindlin-1 isoforms. JPathol 2007, 213:462-470.
64. Fiskerstrand T., Arshad N., Haukanes B.I., et al. Familial diarrhea syndrome caused by an activating GUCY2C mutation. NEngl J Med 2012, 366:1586-1595.
65. Chalaris A., Adam N., Sina C., et al. Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. JExp Med 2010, 207:1617-1624.
66. Nenci A., Becker C., Wullaert A., et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007, 446:557-561.
67. Zaph C., Troy A.E., Taylor B.C., et al. Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature 2007, 446:552-556.
68. Cheng L.E., Kanwar B., Tcheurekdjian H., et al. Persistent systemic inflammation and atypical enterocolitis in patients with NEMO syndrome. Clin Immunol 2009, 132:124-131.
69. Luetteke N.C., Qiu T.H., Peiffer R.L., et al. TGF alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. Cell 1993, 73:263-278.
70. Mann G.B., Fowler K.J., Gabriel A., et al. Mice with a null mutation of the TGF alpha gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. Cell 1993, 73:249-261.
71. Strober W., Fuss I.J., Blumberg R.S. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002, 20:495-549.
72. Hand T.W., Dos Santos L.M., Bouladoux N., et al. Acute gastrointestinal infection induces long-lived microbiota-specific T cell responses. Science 2012, 337:1553-1556.
73. Cong Y., Feng T., Fujihashi K., et al. Adominant, coordinated T regulatory cell-IgA response to the intestinal microbiota. Proc Natl Acad Sci USA 2009, 106:19256-19261.
74. Mombaerts P., Iacomini J., Johnson R.S., et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992, 68:869-877.
75. Shinkai Y., Rathbun G., Lam K.P., et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992, 68:855-867.
76. Peschon J.J., Morrissey P.J., Grabstein K.H., et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. JExp Med 1994, 180:1955-1960.
77. Pieper K., Grimbacher B., Eibel H. B-cell biology and development. JAllergy Clin Immunol 2013, 131:959-971.
78. Vetrie D., Vorechovsky I., Sideras P., et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993, 361:226-233.
79. Conley M.E., Notarangelo L.D., Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 1999, 93:190-197.
80. Pai S.Y., Cowan M.J. Stem cell transplantation for primary immunodeficiency diseases: the North American experience. Curr Opin Allergy Clin Immunol 2014, 14:521-526.
81. Shearer W.T., Dunn E., Notarangelo L.D., et al. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. JAllergy Clin Immunol 2014, 133:1092-1098.
82. + severe combined immunodeficiency. Nat Genet 1998, 20:394-397.
83. Dadi H.K., Simon A.J., Roifman C.M. Effect of CD3delta deficiency on maturation of alpha/beta and gamma/delta T-cell lineages in severe combined immunodeficiency. NEngl J Med 2003, 349:1821-1828.
84. Nielsen C., Jakobsen M.A., Larsen M.J., et al. Immunodeficiency associated with a nonsense mutation of IKBKB. JClin Immunol 2014, 34:916-921.
85. Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. 1994;78:635-644.
86. Watanabe Y., Sasahara Y., Ramesh N., et al. T-cell receptor ligation causes Wiskott-Aldrich syndrome protein degradation and F-actin assembly downregulation. JAllergy Clin Immunol 2013, 132:648-655.e1.
87. Shimizu M., Kanegane H., Wada T., et al. Aberrant glycosylation of IgA in Wiskott-Aldrich syndrome and X-linked thrombocytopenia. JAllergy Clin Immunol 2013, 131:587-590. e1-3.
88. Westerberg L.S., Dahlberg C., Baptista M., et al. Wiskott-Aldrich syndrome protein (WASP) and N-WASP are critical for peripheral B-cell development and function. Blood 2012, 119:3966-3974.
89. Becker-Herman S., Meyer-Bahlburg A., Schwartz M.A., et al. WASp-deficient B cells play a critical, cell-intrinsic role in triggering autoimmunity. JExp Med 2011, 208:2033-2042.
90. Lanzi G., Moratto D., Vairo D., et al. Anovel primary human immunodeficiency due to deficiency in the WASP-interacting protein WIP. JExp Med 2012, 209:29-34.
91. Nguyen D.D., Maillard M.H., Cotta-de-Almeida V., et al. Lymphocyte-dependent and Th2 cytokine-associated colitis in mice deficient in Wiskott-Aldrich syndrome protein. Gastroenterology 2007, 133:1188-1197.
92. + regulatory T cells. JExp Med 2007, 204:381-391.
93. Nguyen D.D., Wurbel M.A., Goettel J.A., et al. Wiskott-Aldrich syndrome protein deficiency in innate immune cells leads to mucosal immune dysregulation and colitis in mice. Gastroenterology 2012, 143:719-729. e1-2.
94. van der Vliet H.J., Nieuwenhuis E.E. IPEX as a result of mutations in FOXP3. Clin Dev Immunol 2007, 2007:89017.
95. Torgerson T.R., Ochs H.D. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. JAllergy Clin Immunol 2007, 120:744-750.
96. Barzaghi F., Passerini L., Bacchetta R. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: a paradigm of immunodeficiency with autoimmunity. Front Immunol 2012, 3:211.
97. Zeissig S., Petersen B.S., Tomczak M., et al. Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4. Gut 2014, Published online. http://dx.doi.org/10.1136/gutjnl-2014-308541.
98. Cebula A., Seweryn M., Rempala G.A., et al. Thymus-derived regulatory T cells contribute to tolerance to commensal microbiota. Nature 2013, 497:258-262.
99. Josefowicz S.Z., Lu L.F., Rudensky A.Y. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012, 30:531-564.
100. Lathrop S.K., Bloom S.M., Rao S.M., et al. Peripheral education of the immune system by colonic commensal microbiota. Nature 2011, 478:250-254.
101. Chinen T., Volchkov P.Y., Chervonsky A.V., et al. Acritical role for regulatory T cell-mediated control of inflammation in the absence of commensal microbiota. JExp Med 2010, 207:2323-2330.
102. Schultz M., Tonkonogy S.L., Sellon R.K., et al. IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation. Am J Physiol 1999, 276:G1461-G1472.
103. Schiering C., Krausgruber T., Chomka A., et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 2014, 513:564-568.
104. Shim J.O., Hwang S., Yang H.R., et al. Interleukin-10 receptor mutations in children with neonatal-onset Crohn's disease and intractable ulcerating enterocolitis. Eur J Gastroenterol Hepatol 2013, 25:1235-1240.
105. Moore K.W., de Waal Malefyt R., Coffman R.L., et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
106. Hutchins A.P., Diez D., Miranda-Saavedra D. The IL-10/STAT3-mediated anti-inflammatory response: recent developments and future challenges. Brief Funct Genomics 2013, 12:489-498.
107. Engelhardt K.R., Grimbacher B. IL-10 in humans: lessons from the gut, IL-10/IL-10 receptor deficiencies, and IL-10 polymorphisms. Curr Top Microbiol Immunol 2014, 380:1-18.
108. Murray P.J. The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. Proc Natl Acad Sci USA 2005, 102:8686-8691.
109. Neven B., Mamessier E., Bruneau J., et al. AMendelian predisposition to B-cell lymphoma caused by IL-10R deficiency. Blood 2013, 122:3713-3722.
110. Engelhardt K.R., Shah N., Faizura-Yeop I., et al. Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. JAllergy Clin Immunol 2013, 131:825-830.
111. Murugan D., Albert M.H., Langemeier J., et al. Very early onset inflammatory bowel disease associated with aberrant trafficking of IL-10R1 and cure by T cell replete haploidentical bone marrow transplantation. JClin Immunol 2014, 34:331-339.
112. Kuhn R., Lohler J., Rennick D., et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75:263-274.
113. Sellon R.K., Tonkonogy S., Schultz M., et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998, 66:5224-5231.
114. Rubtsov Y.P., Rasmussen J.P., Chi E.Y., et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008, 28:546-558.
115. Roers A., Siewe L., Strittmatter E., et al. Tcell-specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. JExp Med 2004, 200:1289-1297.
116. Shouval D.S., Biswas A., Goettel J.A., et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. Immunity 2014, 40:706-719.
117. Zigmond E., Bernshtein B., Friedlander G., et al. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. Immunity 2014, 40:720-733.
118. Sonnenberg G.F., Fouser L.A., Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 2011, 12:383-390.
119. Sonnenberg G.F., Artis D. Innate lymphoid cell interactions with microbiota: implications for intestinal health and disease. Immunity 2012, 37:601-610.
120. Spits H., Artis D., Colonna M., et al. Innate lymphoid cells-a proposal for uniform nomenclature. Nat Rev Immunol 2013, 13:145-149.
121. Sonnenberg G.F., Monticelli L.A., Alenghat T., et al. Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science 2012, 336:1321-1325.
122. + T-cell responses to intestinal commensal bacteria. Nature 2013, 498:113-117.
123. Bernink J.H., Peters C.P., Munneke M., et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol 2013, 14:221-229.
124. Geremia A., Arancibia-Carcamo C.V., Fleming M.P., et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. JExp Med 2011, 208:1127-1133.
125. + natural killer cells in the intestinal mucosa of patients with Crohn's disease. Gastroenterology 2010, 139:882-892. e1-3.
126. + natural killer cells in subclinical gut inflammation in ankylosing spondylitis. Arthritis Rheum 2012, 64:1869-1878.
127. Fuchs A., Vermi W., Lee J.S., et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-gamma-producing cells. Immunity 2013, 38:769-781.
128. + T cells. Science 2015, 348:1031-1035.
129. Kang E.M., Marciano B.E., DeRavin S., et al. Chronic granulomatous disease: overview and hematopoietic stem cell transplantation. JAllergy Clin Immunol 2011, 127:1319-1326.
130. Abo A., Pick E., Hall A., et al. Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. Nature 1991, 353:668-670.
131. Matute J.D., Arias A.A., Wright N.A., et al. Anew genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. Blood 2009, 114:3309-3315.
132. Jones L.B., McGrogan P., Flood T.J., et al. Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin Exp Immunol 2008, 152:211-218.
133. Rosenzweig S.D. Inflammatory manifestations in chronic granulomatous disease (CGD). JClin Immunol 2008, 28(Suppl 1):S67-S72.
134. Foster C.B., Lehrnbecher T., Mol F., et al. Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. JClin Invest 1998, 102:2146-2155.
135. Muise A.M., Xu W., Guo C.H., et al. NADPH oxidase complex and IBD candidate gene studies: identification of a rare variant in NCF2 that results in reduced binding to RAC2. Gut 2012, 61:1028-1035.
136. Dhillon S.S., Fattouh R., Elkadri A., et al. Variants in nicotinamide adenine dinucleotide phosphate oxidase complex components determine susceptibility to very early onset inflammatory bowel disease. Gastroenterology 2014, 147:680-689.e2.
137. Roos D., Law S.K. Hematologically important mutations: leukocyte adhesion deficiency. Blood Cells Mol Dis 2001, 27:1000-1004.
138. van de Vijver E., Maddalena A., Sanal O., et al. Hematologically important mutations: leukocyte adhesion deficiency (first update). Blood Cells Mol Dis 2012, 48:53-61.
139. Schmidt S., Moser M., Sperandio M. The molecular basis of leukocyte recruitment and its deficiencies. Mol Immunol 2013, 55:49-58.
140. Davis M.K., Rufo P.A., Polyak S.F., et al. Adalimumab for the treatment of Crohn-like colitis and enteritis in glycogen storage disease type Ib. JInherit Metab Dis 2008, 31(Suppl 3):505-509.
141. Uzel G., Orange J.S., Poliak N., et al. Complications of tumor necrosis factor-alpha blockade in chronic granulomatous disease-related colitis. Clin Infect Dis 2010, 51:1429-1434.
142. Kato K., Kojima Y., Kobayashi C., et al. Successful allogeneic hematopoietic stem cell transplantation for chronic granulomatous disease with inflammatory complications and severe infection. Int J Hematol 2011, 94:479-482.
143. de Luca A., Smeekens S.P., Casagrande A., et al. IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proc Natl Acad Sci USA 2014, 111:3526-3531.
144. Bianco A.M., Girardelli M., Vozzi D., et al. Mevalonate kinase deficiency and IBD: shared genetic background. Gut 2014, 63:1367-1368.
145. Kuloglu Z., Kansu A., Ustundag G., et al. An infant with severe refractory Crohn's disease and homozygous MEFV mutation who dramatically responded to colchicine. Rheumatol Int 2012, 32:783-785.
146. Beser O.F., Kasapcopur O., Cokugras F.C., et al. Association of inflammatory bowel disease with familial Mediterranean fever in Turkish children. JPediatr Gastroenterol Nutr 2013, 56:498-502.
147. Mora A.J., Wolfsohn D.M. The management of gastrointestinal disease in Hermansky-Pudlak syndrome. JClin Gastroenterol 2011, 45:700-702.
148. Almeida de Jesus A., Goldbach-Mansky R. Monogenic autoinflammatory diseases: concept and clinical manifestations. Clin Immunol 2013, 147:155-174.
149. Speckmann C., Lehmberg K., Albert M.H., et al. X-linked inhibitor of apoptosis (XIAP) deficiency: the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis. Clin Immunol 2013, 149:133-141.
150. Latour S., Aguilar C. XIAP deficiency syndrome in humans. Semin Cell Dev Biol 2015, 39:115-123.
151. Pedersen J., LaCasse E.C., Seidelin J.B., et al. Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation. Trends Mol Med 2014, 20:652-665.
152. Aguilar C., Latour S. X-linked inhibitor of apoptosis protein deficiency: more than an X-linked lymphoproliferative syndrome. JClin Immunol 2015, 35:331-338.
153. Filipovich A.H. The expanding spectrum of hemophagocytic lymphohistiocytosis. Curr Opin Allergy Clin Immunol 2011, 11:512-516.